At the ASCRS congress from
Rolando Toyos, of Toyos Clinicin Nashville, TNwill present the study results from his peer-reviewed publication in the Journal of Clinical & Experimental Ophthalmology. The study included 26 eyes and illustrated a reduction of IOP from a baseline of 25.6 mmHg to 18 mmHg at 6-12 months and a reduction in the number of topical glaucoma medications required from an average of 3.3 to 1.8.
Thomas Samuelsonand Mark Hansenfrom Minnesota Eye Consultantswill present results from a study that reviewed 119 procedures and concludes that MicroPulse is an effective, non-invasive treatment to lower IOP and is a viable option for all types of glaucoma at various stages.
Jeffrey Kammerof Vanderbilt Eye Institutewill speak on MicroPulse in his cyclophotocoagulation talk during the session entitled, "Changing Paradigms in Glaucoma Laser Surgery: What Laser Do I Use When?".
Thomas Johnfrom Loyola University at Chicagowill present results from a study that evaluated the treatment of 20 eyes resulting in a reduction in IOP and topical medication with no adverse events.
At the ARVO annual meeting from
- Doheny Eye Center UCLA, Dr.
Brian Francis, 20 eyes, 43% IOP reduction @ approximately 2 months follow-up. University of Missouri, Dr. Rohit Krishna, 30 patients, 43% IOP reduction @ 6 months follow-up. Wills Eye Hospital, Dr. Marlene Moster, 78 patients, 50% IOP reduction @ an average of 7.5 months follow-up. University of Washington, Dr. Murray Johnstone, "Clinically used MicroPulse parameters induce outflow system configuration changes generally associated with improved aqueous flow."
- UCSF, Dr.
Shan Lin, "No presence of suprachoroidal fluid or anatomical changes were found." The study concluded, "MP-TCP is effective at lowering IOP in the majority of patients and appears safe without major complications."
Also at ARVO, four studies will be presented on MicroPulse laser therapy for diabetic macular edema (DME) and central serous chorioretinopathy (CSC). Results from a 3-year study demonstrated that MicroPulse laser monotherapy for DME maintains its efficacy in stabilizing / improving visual acuity and in reducing / eliminating DME. Two other studies examined retinal layer changes post MicroPulse for DME, and found improvement in both morphologic and functional (retinal sensitivity) outcomes, and no structural damage to the underlying photoreceptor layer while still achieving effective results. In addition, results from a 6-month study on MicroPulse monotherapy for the treatment of chronic CSC demonstrated safety and clinical efficacy.
"We are very encouraged by this data, further illustrating consistent clinical safety and efficacy results for our MicroPulse technology," stated
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the presentation and development of clinical data related to the Company's products, future demand and order levels for the Company's products, future operating expenses, changes in personnel, product development and intellectual property related matters, the adoption and effect of Company products on its results, the markets in which the Company operates, usage and efficacy of the Company's products, the Company's future financial results, and the Company's strategic plans and objectives. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/iridex-announces-presentation-of-data-demonstrating-safety-and-efficacy-of-micropulse-technology-at-upcoming-industry-conferences-300451748.html
Lynn Pieper Lewis or Leigh Salvo, (415) 937-5404, firstname.lastname@example.org